The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinicopathological features of ruptured GIST in the ReGISTry study of high risk GIST patients after complete resection in Japan.
 
Toshirou Nishida
Honoraria - Bayer; Novartis; Pfizer
Research Funding - Bayer; Novartis
 
Masato Kondo
No Relationships to Disclose
 
Masato Ozaka
No Relationships to Disclose
 
Haruhiko Cho
Honoraria - Bayer; Novartis; Pfizer
 
Yoshito Komatsu
Honoraria - Bayer; Novartis; Pfizer
Speakers' Bureau - Bayer; Novartis; Pfizer
Research Funding - Bayer; Novartis; Pfizer
 
Toshihiko Doi
Honoraria - Chugai Pharma; Novartis
Consulting or Advisory Role - Amgen; Lilly Japan; Merck Serono; Otsuka
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zenyaku Kogyo (Inst)
 
Hideo Baba
No Relationships to Disclose
 
Yuko Kitagawa
Honoraria - Chugai Pharma; Ethicon; Nippon Kayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ajinomoto (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); GlaxoSmithKline (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kureha (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Medtronic (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Novartis (Inst); Otsuka (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Taisho Toyama Pharma (Inst); Takeda (Inst); Teijin Pharma (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)
 
Yukinori Kurokawa
Honoraria - Novartis
 
Tetsuo Kanda
Consulting or Advisory Role - Novartis
 
Toshiro Sugiyama
Research Funding - Novartis (Inst); Pfizer (Inst)
 
Akira Sawaki
Honoraria - Novartis; Pfizer
 
Yoshihiro Kakeji
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Toshihiro Hirai
No Relationships to Disclose
 
Shinji Hato
No Relationships to Disclose
 
Kuniaki Shirao
No Relationships to Disclose
 
Chikashi Ishioka
Speakers' Bureau - Asahi Kasei; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Merck Serono; Mochida Pharmaceutical Co. Ltd.; Nichi-iko; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Merck Serono; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Seiichi Hirota
No Relationships to Disclose
 
Tatsuo Kagimura
No Relationships to Disclose
 
Masakazu Takagi
No Relationships to Disclose